Response to Letter to the Editor

Published:November 07, 2021DOI:
      We are appreciative of having the opportunity to respond to the “Letter to the Editor” by Neal et al regarding our publication, “Pediatric-Antiresorptive Use: Should We Intervene on Third Molars Early?”.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ruggiero SL
        • Dodson TB
        • Fantasia J
        • et al.
        American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update.
        J Oral Maxillofac Surg. 2014; 72: 1938-1956
        • Bone HG
        • Wagman RB
        • Brandi ML
        • et al.
        10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
        Lancet Diabetes Endocinol. 2017; 5: 513-523
        • Eghbali-Fatourechi G.
        Bisphosphonate therapy in pediatric patients.
        J Diabetes Metab Disord. 2014; 13: 109
        • Dhanrajani A
        • Khubchandani RP.
        Bisphosphosphonates in pediatric rheumatology: a review.
        Int J Clin Rheumatol. 2018; 13: 179-184
        • Pogrel MA
        • Dodson TB
        • Swift JQ
        • et al.
        White Paper on Third Molar Data.
        AAOMS, 2007